Dexcom annual shareholders’ equity
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Dexcom Shareholders’ Equity Growth & History (DXCM)
Dexcom's shareholders’ equity was $2.75B for fiscal 2025.
View full Dexcom company overviewDexcom annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.75B | $643.4M | +30.60% |
| 2024 | 2024-12-31 | $2.10B | $34.0M | +1.64% |
| 2023 | 2023-12-31 | $2.07B | −$63.2M | −2.96% |
| 2022 | 2022-12-31 | $2.13B | $89.7M | +4.39% |
| 2021 | 2021-12-31 | $2.04B | $490.2M | +31.59% |
| 2020 | 2020-12-31 | $1.55B | $669.3M | +75.83% |
| 2019 | 2019-12-31 | $882.6M | $219.3M | +33.06% |
| 2018 | 2018-12-31 | $663.3M | $243.9M | +58.15% |
| 2017 | 2017-12-31 | $419.4M | $135.6M | +47.78% |
| 2016 | 2016-12-31 | $283.8M | $62.6M | +28.30% |
| 2015 | 2015-12-31 | $221.2M | $81.0M | +57.77% |
| 2014 | 2014-12-31 | $140.2M | $56.1M | +66.71% |
| 2013 | 2013-12-31 | $84.1M | $7.1M | +9.22% |
| 2012 | 2012-12-31 | $77.0M | −$27.5M | −26.32% |
| 2011 | 2011-12-31 | $104.5M | $43.5M | +71.31% |
| 2010 | 2010-12-31 | $61.0M | $79.4M | — |
| 2009 | 2009-12-31 | −$18.4M | — | — |
Dexcom quarterly shareholders’ equity
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.62B | $48.3M | +1.88% |
| Q1 2026 | 2026-03-31 | $2.96B | $690.3M | +30.46% |
| Q4 2025 | 2025-12-31 | $2.75B | $643.4M | +30.60% |
| Q3 2025 | 2025-09-30 | $2.73B | $747.1M | +37.75% |
| Q2 2025 | 2025-06-30 | $2.57B | $138.8M | +5.70% |
| Q1 2025 | 2025-03-31 | $2.27B | $19.8M | +0.88% |
| Q4 2024 | 2024-12-31 | $2.10B | $34.0M | +1.64% |
| Q3 2024 | 2024-09-30 | $1.98B | −$288.9M | −12.74% |
| Q2 2024 | 2024-06-30 | $2.43B | $333.9M | +15.90% |
| Q1 2024 | 2024-03-31 | $2.25B | $13.8M | +0.62% |
| Q4 2023 | 2023-12-31 | $2.07B | −$63.2M | −2.96% |
| Q3 2023 | 2023-09-30 | $2.27B | $443.4M | +24.30% |
| Q2 2023 | 2023-06-30 | $2.10B | −$155.5M | −6.89% |
| Q1 2023 | 2023-03-31 | $2.23B | $43.7M | +2.00% |
| Q4 2022 | 2022-12-31 | $2.13B | $89.7M | +4.39% |
| Q3 2022 | 2022-09-30 | $1.82B | −$87.5M | −4.58% |
| Q2 2022 | 2022-06-30 | $2.26B | $501.2M | +28.56% |
| Q1 2022 | 2022-03-31 | $2.19B | $544.5M | +33.10% |
| Q4 2021 | 2021-12-31 | $2.04B | $490.2M | +31.59% |
| Q3 2021 | 2021-09-30 | $1.91B | $412.7M | +27.53% |
| Q2 2021 | 2021-06-30 | $1.75B | $400.8M | +29.60% |
| Q1 2021 | 2021-03-31 | $1.64B | $710.3M | +76.01% |
| Q4 2020 | 2020-12-31 | $1.55B | $669.3M | +75.83% |
| Q3 2020 | 2020-09-30 | $1.50B | $735.0M | +96.17% |
| Q2 2020 | 2020-06-30 | $1.35B | $665.6M | +96.70% |
| Q1 2020 | 2020-03-31 | $934.5M | $265.9M | +39.77% |
| Q4 2019 | 2019-12-31 | $882.6M | $219.3M | +33.06% |
| Q3 2019 | 2019-09-30 | $764.3M | $202.1M | +35.95% |
| Q2 2019 | 2019-06-30 | $688.3M | $206.2M | +42.77% |
| Q1 2019 | 2019-03-31 | $668.6M | $246.9M | +58.55% |
| Q4 2018 | 2018-12-31 | $663.3M | $243.9M | +58.15% |
| Q3 2018 | 2018-09-30 | $562.2M | $178.2M | +46.41% |
| Q2 2018 | 2018-06-30 | $482.1M | $128.4M | +36.30% |
| Q1 2018 | 2018-03-31 | $421.7M | $143.9M | +51.80% |
| Q4 2017 | 2017-12-31 | $419.4M | $135.6M | +47.78% |
| Q3 2017 | 2017-09-30 | $384.0M | $122.2M | +46.68% |
| Q2 2017 | 2017-06-30 | $353.7M | $107.3M | +43.55% |
| Q1 2017 | 2017-03-31 | $277.8M | $46.6M | +20.16% |
| Q4 2016 | 2016-12-31 | $283.8M | $62.6M | +28.30% |
| Q3 2016 | 2016-09-30 | $261.8M | $68.5M | +35.44% |
| Q2 2016 | 2016-06-30 | $246.4M | $75.7M | +44.35% |
| Q1 2016 | 2016-03-31 | $231.2M | $82.6M | +55.59% |
| Q4 2015 | 2015-12-31 | $221.2M | $81.0M | +57.77% |
| Q3 2015 | 2015-09-30 | $193.3M | $78.3M | +68.09% |
| Q2 2015 | 2015-06-30 | $170.7M | $71.1M | +71.39% |
| Q1 2015 | 2015-03-31 | $148.6M | $58.6M | +65.11% |
| Q4 2014 | 2014-12-31 | $140.2M | $56.1M | +66.71% |
| Q3 2014 | 2014-09-30 | $115.0M | $40.3M | +53.95% |
| Q2 2014 | 2014-06-30 | $99.6M | $27.3M | +37.76% |
| Q1 2014 | 2014-03-31 | $90.0M | $16.4M | +22.28% |
| Q4 2013 | 2013-12-31 | $84.1M | $7.1M | +9.22% |
| Q3 2013 | 2013-09-30 | $74.7M | −$5.6M | −6.92% |
| Q2 2013 | 2013-06-30 | $72.3M | −$19.0M | −20.82% |
| Q1 2013 | 2013-03-31 | $73.6M | −$26.0M | −26.07% |
| Q4 2012 | 2012-12-31 | $77.0M | −$27.5M | −26.32% |
| Q3 2012 | 2012-09-30 | $80.3M | −$32.8M | −29.02% |
| Q2 2012 | 2012-06-30 | $91.3M | −$30.3M | −24.90% |
| Q1 2012 | 2012-03-31 | $99.6M | — | — |
| Q4 2011 | 2011-12-31 | $104.5M | $43.5M | +71.33% |
| Q3 2011 | 2011-09-30 | $113.1M | — | — |
| Q2 2011 | 2011-06-30 | $121.6M | — | — |
| Q4 2010 | 2010-12-31 | $61.0M | — | — |
Dexcom shareholders’ equity trends
Over the last five fiscal years, Dexcom's shareholders’ equity increased from $1.55B to $2.75B, a change of $1.19B. The latest reported quarter, Q2 2026, shows $2.62B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dexcom source filings ↗Community posts
Dexcom raises revenue and margin targets and authorizes a $1 billion buyback
Dexcom ($DXCM) lifted its 2026 sales forecast to $5.20–$5.25 billion, raising the midpoint, and increased its adjusted operating-margin target to approximately 24%. Third-quarter 2026 revenue increased 11% to $1.34 billion, with US growth o ...
